Verrica Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview

Verrica Pharmaceuticals

07/08/2023 19:33

* Verrica Pharmaceuticals Inc  VRCA.OQ   VRCA.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 9 (estimated). 
    * The West Chester Pennsylvania-based  company is expected
to
report  a 66.4% decrease in revenue to $72 thousand from $214
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Verrica
Pharmaceuticals
Inc is for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Verrica
Pharmaceuticals Inc is $12.5​, above​ its last closing price
of $5.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.18       -0.19      -0.15     Beat    21.1
 Dec. 31 2023  -0.19       -0.19      -0.14     Beat    27.3
 Sep. 30 2022  -0.17       -0.11      0.03      Beat    126.4​
 Jun. 30 2022  -0.28       -0.32      -0.37     Missed  -15.3
 ​​Mar.        -0.45       -0.47      -0.31     Beat    34.3
 31 2022                                                
 Dec. 31 2021  -0.48       -0.50      -0.35     Beat    29.6​
 Sep. 30 2021  -0.52       -0.51      -0.47     Beat    7.5
 Jun. 30 2021  -0.37       -0.41      -0.43     Missed  -3.9
 This summary was machine generated August 7 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated